What it's for (Indications)
- Methylprednisolone aceponate, topical + metronidazole, topical (e.
- g.
- , Revomet Plus Gel) is indicated for the short-term treatment of various inflammatory skin conditions that are responsive to potent topical corticosteroids and where a secondary microbial component susceptible to metronidazole is present or suspected.
- This includes certain forms of eczema, dermatitis, or other inflammatory dermatoses exhibiting signs of concurrent bacterial (particularly anaerobic) or parasitic (e.
- g.
- , Demodex) involvement where a potent corticosteroid is deemed appropriate to reduce inflammation and pruritus.
- The combination aims to mitigate inflammation, itching, and address microbial elements or inflammatory processes that respond to metronidazole.
- The decision for its use must be based on a thorough clinical assessment, weighing the benefits against the potential risks associated with the potent corticosteroid component, ensuring its application is appropriate for the specific dermatological condition.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | A thin layer of the gel should be applied to the affected skin area(s) once or twice daily, as directed by a healthcare professional. The treatment duration must be strictly limited, typically not exceeding two to four weeks, especially when applied to large body surface areas, intertriginous zones (e.g., groin, armpits), or under occlusive dressings, to minimize the risk of systemic absorption and local adverse effects associated with the potent corticosteroid component. Pediatric use requires particular caution and should be for the shortest possible duration. The specific frequency, duration of application, and total quantity used must be meticulously determined by the prescribing physician, tailored to the patient's condition, age, and response to therapy, always adhering to the lowest effective dose for the shortest possible time. Not intended for ophthalmic, oral, or intravaginal use. |
Safety & Warnings
Common Side Effects
- Common local side effects associated with this combination therapy may include burning, stinging, itching, dryness, erythema, irritation, and skin atrophy, which are primarily attributed to the potent corticosteroid component.
- Prolonged or extensive use of the corticosteroid can lead to more serious local adverse effects such as irreversible striae (stretch marks), telangiectasias (spider veins), hypertrichosis (excessive hair growth), hypopigmentation (lightening of the skin), acneiform eruptions, folliculitis, perioral dermatitis, and secondary skin infections.
- Systemic absorption, though uncommon with appropriate topical use, can lead to adverse effects including hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria, particularly in children or with occlusive dressings.
- Metronidazole, topically, may cause local irritation, stinging, or dryness; systemic side effects are rare but can include a metallic taste, nausea, or headache in cases of significant absorption.
Serious Warnings
- Black Box Warning: No FDA-mandated black box warning is specifically associated with topical methylprednisolone aceponate or topical metronidazole, either individually or in combination. However, due to the presence of methylprednisolone aceponate, a potent corticosteroid, this product carries significant risks that warrant a serious warning. Prolonged use or application to extensive body surface areas, intertriginous areas, or under occlusive dressings can lead to substantial systemic absorption, potentially resulting in hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria. Such systemic effects are particularly concerning in pediatric patients, who may be more susceptible due to a larger skin surface area-to-body weight ratio. Local adverse effects, including irreversible skin atrophy, striae, and telangiectasias, can also occur, especially with long-term facial use. Therefore, treatment duration should be strictly limited, and patients should be carefully monitored for signs of systemic corticosteroid absorption and irreversible local skin changes. Discontinue use if signs of irritation, sensitization, or lack of improvement occur.
- This combination product requires extreme caution due to the presence of methylprednisolone aceponate, a potent corticosteroid.
- Prolonged use, application to extensive body surface areas, intertriginous areas, or under occlusive dressings significantly increases the risk of systemic absorption, potentially leading to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia.
- Pediatric patients are particularly susceptible to systemic toxicity due to a larger skin surface area-to-body weight ratio.
- Avoid contact with eyes, as it may cause glaucoma or cataracts.
- If irritation, sensitization, or superinfection occurs, discontinue use and institute appropriate therapy.
- The corticosteroid component may mask or exacerbate existing skin infections; therefore, concurrent appropriate antimicrobial therapy is essential if an infection is present.
- Not intended for ophthalmic, oral, or intravaginal use.
- Use in pregnant or lactating women should only be considered if the potential benefit unequivocally justifies the potential risk to the fetus or infant, and only under strict medical supervision.
- Avoid long-term continuous topical therapy in all patients, and exercise particular caution when treating facial areas where skin atrophy is more readily apparent.
How it Works (Mechanism of Action)
Methylprednisolone aceponate is a highly potent synthetic corticosteroid that exerts its anti-inflammatory, antipruritic, and vasoconstrictive effects through a genomic mechanism. It induces the synthesis of phospholipase A2 inhibitory proteins, known as lipocortins, which in turn control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. It also reduces capillary permeability and leukocyte migration. Metronidazole is a nitroimidazole antimicrobial agent. Its mechanism of action involves cellular uptake by susceptible organisms, reduction of its nitro group to reactive nitroso radicals and free radicals, which subsequently damage microbial DNA and other macromolecules, leading to cell death. Topically, metronidazole also exhibits potent anti-inflammatory properties, reducing reactive oxygen species, and inhibiting chemotaxis of neutrophils, thus contributing to its efficacy in inflammatory dermatoses. In combination, these agents provide both potent anti-inflammatory action and targeted antimicrobial/anti-inflammatory effects against susceptible pathogens or inflammatory processes.
Commercial Brands (Alternatives)
No other brands found for this formula.